Get started
Author

Adam P. Stockmann

Observed names: Adam P Stockmann, Adam Stockmann
ORCID: 0000-0002-5222-3156
Observed ORCID: 0000-0002-5222-3156
OpenAlex ID: A5046826075
Intestinal Npt2b Plays a Major Role in Phosphate Absorption and Homeostasis
2009 · Yves Sabbagh, Stephen P. O'Brien, et al. · Journal of the American Society of Nephrology · 354
Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8+ T Cell Responses with Antitumor Activity
2022 · Matthew G Booty, Kelan A Hlavaty, et al. · The Journal of Immunology · 23
Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice
2022 · Katarina Blagovic, Carolyne K. Smith, et al. · Frontiers in Immunology · 11
Abstract 3209: CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models
2016 · Douglas Lazarus, Christian Peters, et al. · Cancer Research · 6
141 PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants
2020 · Matthew Booty, Adam Stockmann, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
170 Microfluidics cell squeezing enables potent cellular vaccines in murine models through direct cytosolic loading and direct CD8 T cell priming
2020 · Emrah Ozay, Matthew Booty, et al. · Journal for ImmunoTherapy of Cancer · 2
DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity
2025 · Adam P. Stockmann, Sylvia Vincent, et al. · Cell Reports Medicine · 1
Abstract 3516: TriNKETs®: trispecific immune cell engager therapies exhibit potent preclinical in vivo anti-tumor activity and broad combinability in diverse cancer models
2025 · Colin LaCroix, Adam Stockmann, et al. · Cancer Research · 1
962 A novel alpha-active IL-2-Fc has expanded therapeutic index and robust monotherapy efficacy in mouse cancer models and strong synergy with PD-1 blockade
2024 · Adam P Stockmann, Sylvia Vincent, et al. · Journal for ImmunoTherapy of Cancer
Abstract PR10: Significant improvements in therapeutic index for conjugated payloads using a nanoparticle-drug conjugate (NDC) platform to provide sustained drug release and potentially improved anticancer effects
2017 · Chester Metcalf, Derek van der Poll, et al. · Cancer Research
Abstract 1345: Tumor selective localization of CRLX101, an investigational nanoparticle-drug conjugate of camptothecin
2016 · Christian G. Peters, Douglas Lazarus, et al. · Cancer Research
Teriflunomide Does Not Significantly Affect Primary and Memory Antibody Responses to a Viral Antigen in Mice (P1.215)
2014 · Andrea Edling, Lisa Woodworth, et al. · Neurology
Works count: 12
Citation count: 401
H-index: 4
I10-index: 3
Year
Topic
Type